[go: up one dir, main page]

MX2019003623A - Composiciones y metodos para el tratamiento de afecciones oftalmicas. - Google Patents

Composiciones y metodos para el tratamiento de afecciones oftalmicas.

Info

Publication number
MX2019003623A
MX2019003623A MX2019003623A MX2019003623A MX2019003623A MX 2019003623 A MX2019003623 A MX 2019003623A MX 2019003623 A MX2019003623 A MX 2019003623A MX 2019003623 A MX2019003623 A MX 2019003623A MX 2019003623 A MX2019003623 A MX 2019003623A
Authority
MX
Mexico
Prior art keywords
compositions
methods
ophthalmic conditions
treating ophthalmic
treating
Prior art date
Application number
MX2019003623A
Other languages
English (en)
Inventor
Rigas Basil
Original Assignee
Medicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicon Pharmaceuticals Inc filed Critical Medicon Pharmaceuticals Inc
Publication of MX2019003623A publication Critical patent/MX2019003623A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a composiciones y métodos para tratar afecciones oftálmicas.
MX2019003623A 2016-09-28 2017-09-28 Composiciones y metodos para el tratamiento de afecciones oftalmicas. MX2019003623A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662400955P 2016-09-28 2016-09-28
US201762564595P 2017-09-28 2017-09-28
PCT/US2017/054051 WO2018064354A1 (en) 2016-09-28 2017-09-28 Compositions and methods for treating ophthalmic conditions

Publications (1)

Publication Number Publication Date
MX2019003623A true MX2019003623A (es) 2019-09-23

Family

ID=61760847

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003623A MX2019003623A (es) 2016-09-28 2017-09-28 Composiciones y metodos para el tratamiento de afecciones oftalmicas.

Country Status (7)

Country Link
US (2) US11510931B2 (es)
JP (1) JP7030345B2 (es)
AU (2) AU2017336765B2 (es)
BR (1) BR112019006160A2 (es)
CA (1) CA3038528A1 (es)
MX (1) MX2019003623A (es)
WO (1) WO2018064354A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
HK1217439A1 (zh) 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗
KR102643821B1 (ko) 2015-06-06 2024-03-07 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
MX2018002155A (es) 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc Compuestos deuterados y usos de los mismos.
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
MX2018014868A (es) 2016-06-02 2019-09-13 Cloudbreak Therapeutics Llc Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
MX2019003623A (es) 2016-09-28 2019-09-23 Medicon Pharmaceuticals Inc Composiciones y metodos para el tratamiento de afecciones oftalmicas.
AU2018339096A1 (en) * 2017-09-28 2020-05-07 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
WO2020018498A1 (en) * 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Cyclodextrin formulations
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN111212642A (zh) * 2018-08-29 2020-05-29 奥古根有限公司 眼用组合物及使用方法
CN115869258A (zh) 2018-09-25 2023-03-31 奥尔德拉医疗公司 用于治疗干眼病的调配物
US12383655B2 (en) * 2018-10-19 2025-08-12 Regents Of The University Of Minnesota Methods of isolating and using descemet's membrane and compositions including isolated descemet's membrane
KR102151051B1 (ko) * 2019-01-10 2020-09-02 고려대학교 산학협력단 당뇨병성 백내장 치료 또는 예방용 조성물
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
BR112021026662A2 (pt) * 2019-09-10 2022-04-12 Cloudbreak Therapeutics Llc Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
US20230302032A1 (en) * 2020-08-04 2023-09-28 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
KR20230142548A (ko) 2021-02-03 2023-10-11 에이디에스 테라퓨틱스 엘엘씨 국소 안과용 조성물
US11213551B1 (en) 2021-04-05 2022-01-04 Korb Research, Llc. Ocular treatment compositions and methods of use thereof
BR112023024422A2 (pt) * 2021-05-24 2024-02-20 Medicon Pharmaceuticals Inc Tratamento da dor associada à neuropatia periférica induzida por quimioterapia
CA3220196A1 (en) * 2021-05-24 2022-12-01 Basil Rigas Treating pain associated with diabetic peripheral neuropathy
EP4525826A1 (en) * 2022-05-18 2025-03-26 Glaukos Corporation Novel applications of zwitterions in ophthalmic topical cream compositions and preparations
WO2025111079A1 (en) 2023-11-21 2025-05-30 Medicon Pharmaceuticals, Inc. Isomers of phosphosulindac
WO2025176750A1 (en) 2024-02-23 2025-08-28 Heinrich-Heine-Universität Düsseldorf Dual targeting in a new class of active ingredients

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4309566A (en) 1979-11-05 1982-01-05 Fmc Corporation Plant regulator
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
CN1129400A (zh) 1994-05-06 1996-08-21 阿尔康实验室公司 维生素e生育酚衍生物在眼科组合物中的应用
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
RU26988U1 (ru) 2002-05-06 2003-01-10 Закрытое акционерное общество "ДУКС-ЛИЗИНГ" Кондуктор для сверления отверстий
US20080153746A1 (en) 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
UA86981C2 (ru) 2004-06-23 2009-06-10 Сирион Терапьютикс, Инк. Применение производных ретинила для лечения офтальмических состояний
US20070299124A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
AU2008262491A1 (en) 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
ES2618482T3 (es) 2007-08-10 2017-06-21 Basil Rigas Compuestos antiinflamatorios y usos de los mismos
US20120295979A1 (en) 2011-05-03 2012-11-22 Florida Atlantic University Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress
US20130225529A1 (en) * 2012-02-27 2013-08-29 Basil Rigas Phospho-ester derivatives and uses thereof
KR20150085509A (ko) 2012-09-21 2015-07-23 바질 리가스 염증-관련 장애, 통증 및 열, 피부 장애, 암 및 이의 전암성 질환의 치료용 조성물
JP2016516761A (ja) 2013-04-09 2016-06-09 クレスセット バイオモレキュラー ディスカバリー リミテッド 炎症性眼疾患の局所治療
MX2019003623A (es) 2016-09-28 2019-09-23 Medicon Pharmaceuticals Inc Composiciones y metodos para el tratamiento de afecciones oftalmicas.
AU2018339096A1 (en) 2017-09-28 2020-05-07 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions

Also Published As

Publication number Publication date
US11510931B2 (en) 2022-11-29
US20230293557A1 (en) 2023-09-21
JP2019533016A (ja) 2019-11-14
CA3038528A1 (en) 2018-04-05
WO2018064354A1 (en) 2018-04-05
BR112019006160A2 (pt) 2019-06-18
AU2017336765B2 (en) 2023-06-08
AU2023226711A1 (en) 2023-09-21
AU2017336765A1 (en) 2019-04-18
US20190343848A1 (en) 2019-11-14
JP7030345B2 (ja) 2022-03-07

Similar Documents

Publication Publication Date Title
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2021000077A (es) Composiciones que comprenden cepas bacterianas.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2018006239A (es) Composiciones que comprenden cepas bacterianas.
MX2018006398A (es) Composiciones que comprenden cepas bacterianas.
MX2018006399A (es) Composiciones que comprenden cepas bacterianas.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2017016529A (es) Composiciones que comprenden cepas bacterianas.
MX2017016564A (es) Composiciones que comprenden cepas bacterianas.
GB2541571A (en) Pharmaceutical compositions
MX2017016525A (es) Composiciones que comprenden cepas bacterianas.
MX2017016560A (es) Composiciones que comprenden cepas bacterianas.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MY186271A (en) Ophthalmic compositions and methods of use therefor
EP3687524A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF OPHTHALMIC DISORDERS
PH12017501864A1 (en) Compositions and methods for treating autism
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
PH12017500602A1 (en) Methods for treating ocular conditions
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors